NCT01371019

Brief Summary

The purpose of this study is to to collect and store blood samples that will be utilized to develop a multimarker test to predict preterm delivery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2011

Longer than P75 for all trials

Geographic Reach
1 country

13 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2011

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

June 8, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 10, 2011

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2014

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2015

Completed
Last Updated

June 11, 2015

Status Verified

June 1, 2015

Enrollment Period

3.7 years

First QC Date

June 8, 2011

Last Update Submit

June 9, 2015

Conditions

Keywords

Preterm Birth, Proteomics

Outcome Measures

Primary Outcomes (1)

  • Spontaneous Preterm Birth

    August 2015

Study Arms (2)

Women with preterm delivery

Women without preterm delivery

Eligibility Criteria

Age18 Years - 60 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Pregnant women who are receiving prenatal care.

You may qualify if:

  • Subject is 18 years or older.
  • Subject has a singleton pregnancy.
  • Subject is able to provide consent.

You may not qualify if:

  • Subject is pregnant with more than one fetus.
  • There is a known or suspected fetal anomaly.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (13)

Maricopa Integrated Health System

Phoenix, Arizona, 85008, United States

Location

San Diego Perinatal Clinic

San Diego, California, 92123, United States

Location

Christiana Care Health System

Newark, Delaware, 19713-4248, United States

Location

Baystate Medical Center

Springfield, Massachusetts, 01199, United States

Location

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 25599-1651, United States

Location

Ohio State University

Columbus, Ohio, 43210, United States

Location

Oregon Health and Science University

Portland, Oregon, 97239, United States

Location

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

Location

Regional Obstetrical Consultants

Chattanooga, Tennessee, 37403, United States

Location

University of Texas Medical Branch at Galveston

Galveston, Texas, 77555-0156, United States

Location

Intermountain Medical Center Suite 100, 5121 S. Cottonwood Street ,

Murray, Utah, 84107-5701, United States

Location

McKay-Dee Hospital Center

Ogden, Utah, 84403, United States

Location

LDS Hospital

Salt Lake City, Utah, 84143-0001, United States

Location

Related Publications (1)

  • Esplin MS, Merrell K, Goldenberg R, Lai Y, Iams JD, Mercer B, Spong CY, Miodovnik M, Simhan HN, van Dorsten P, Dombrowski M; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Proteomic identification of serum peptides predicting subsequent spontaneous preterm birth. Am J Obstet Gynecol. 2011 May;204(5):391.e1-8. doi: 10.1016/j.ajog.2010.09.021. Epub 2010 Nov 11.

    PMID: 21074133BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum, plasma

MeSH Terms

Conditions

Premature Birth

Condition Hierarchy (Ancestors)

Obstetric Labor, PrematureObstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Study Officials

  • Durlin E Hickok, MD, MPH

    Sera Prognostics, Inc.

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 8, 2011

First Posted

June 10, 2011

Study Start

April 1, 2011

Primary Completion

December 1, 2014

Study Completion

April 1, 2015

Last Updated

June 11, 2015

Record last verified: 2015-06

Locations